Swiss HIV Cohort Study

Swiss HIV Cohort Study
Name	Swiss HIV Cohort Study
Type	Longitudinal cohort study
Founded	1988
Location	Switzerland
Fields	Epidemiology, Clinical research, Virology

Swiss HIV Cohort Study

The Swiss HIV Cohort Study is a long-term, multicenter observational cohort based in Switzerland that monitors people living with HIV to advance clinical care, public health policy, and biomedical research. It integrates clinical, immunological, virological, and behavioral data collected across university hospitals and cantonal clinics to inform treatment guidelines, resistance surveillance, and epidemiological modeling. The cohort’s work has intersected with major figures and institutions across medicine and public health, informing international efforts in infectious diseases, pharmacology, and health policy.

History and establishment

The cohort was established in 1988 amid global responses to the HIV/AIDS epidemic involving institutions like World Health Organization, Centers for Disease Control and Prevention, University of Geneva, University Hospital Zurich, and collaborations with public health authorities in Bern, Basel, and Lausanne. Its founding drew on expertise from clinicians and researchers affiliated with National Institutes of Health, European Centre for Disease Prevention and Control, University of Oxford, Karolinska Institutet, and clinical networks linked to pioneers such as Françoise Barré-Sinoussi, Luc Montagnier, Anthony Fauci, Robert Gallo, and contributors connected to Swiss National Science Foundation. Early initiatives referenced work published in journals associated with The Lancet, New England Journal of Medicine, Nature, Science, and guidelines influenced by committees like those of UNAIDS and national advisory boards in France, Germany, and Italy.

Study design and methodology

The cohort uses prospective longitudinal follow-up with standardized clinical and laboratory protocols adapted from protocols used at Johns Hopkins University, University College London, Imperial College London, and research centers linked to Harvard Medical School, Massachusetts General Hospital, and Broad Institute. Laboratory methods include immunophenotyping, viral load quantification, and HIV resistance testing performed in reference labs modeled after networks such as EuroSIDA and collaborations with consortia like INSIGHT and START. Statistical analyses have employed methods developed at Columbia University, University of California, San Francisco, McGill University, and ETH Zurich, and have used biostatistical approaches described by authors from Stanford University and Princeton University.

Participant population and recruitment

Participants were recruited through clinics associated with University Hospital Zurich, University Hospital Bern, Hôpital Cantonal de Genève, and community organizations similar to Médecins Sans Frontières and AIDS Healthcare Foundation. The cohort includes demographic groups reflective of migration patterns involving countries such as Portugal, Spain, Nigeria, Brazil, Russia, Romania, Ukraine, and regions tied to travel from Thailand and India. Recruitment strategies referenced community engagement models used by Terrence Higgins Trust, Act Up, Red Cross, and public health campaigns linked to ministries in Canton of Zurich and Canton of Vaud.

Key findings and contributions

Research from the cohort has contributed to treatment paradigms endorsed by panels with members from European Medicines Agency, Food and Drug Administration, Swissmedic, and influenced clinical practice in institutions including Oxford University Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, and Karolinska University Hospital. Notable contributions include data on antiretroviral therapy effectiveness paralleling trials like SMART, START, and HPTN studies; surveillance of transmitted drug resistance relevant to findings by investigators from Vaccine Research Center and Institut Pasteur; investigations into comorbidities connecting to work at Mayo Clinic, Cleveland Clinic, Mount Sinai Health System, and Johns Hopkins Hospital. The cohort’s outputs intersect with literature authored by researchers affiliated with WHO, UNAIDS, Bill & Melinda Gates Foundation, Wellcome Trust, and policy bodies in European Union health frameworks.

Governance, funding, and ethics

Governance structures include steering committees and ethics oversight similar to frameworks at Ethics Committee of the Canton of Zurich, institutional boards at University of Basel, and oversight modeled after multinational consortia like ISARIC and European HIV cohort collaboration. Funding sources have included national agencies such as Swiss National Science Foundation and philanthropic or international funders like European Commission, Bill & Melinda Gates Foundation, Wellcome Trust, and bilateral programs involving United States Agency for International Development and foundations connected to Rockefeller Foundation. Ethical review processes align with declarations and standards related to Declaration of Helsinki and guidelines from organizations like Council of Europe and European Medicines Agency.

Data access and collaborations

Data governance and sharing policies facilitate collaborations with academic partners at University of Cambridge, University of Edinburgh, KU Leuven, Hôpital Saint-Antoine, and research networks including EuroCoord and PANGEA-HIV. The cohort has participated in pooled analyses with consortia such as COHERE, INSIGHT, EuroSIDA, and collaborations with pharmaceutical partners including entities related to Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, and vaccine efforts involving Moderna and Pfizer. Data access is managed to enable secondary research while protecting participant privacy in accordance with standards referenced by European Data Protection Board and institutional review boards at ETH Zurich and university hospitals across Switzerland.

Category:Epidemiology cohorts